| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. | JAMA | 1992 | 1.13 |
| 2 | Early dosing practices and effectiveness of recombinant human erythropoietin. | Kidney Int | 1993 | 1.07 |
| 3 | Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. | J Am Soc Nephrol | 1994 | 0.93 |
| 4 | The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. | Med Care | 1994 | 0.93 |
| 5 | Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98. | Health Care Financ Rev | 1999 | 0.85 |
| 6 | Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. | Semin Nephrol | 2000 | 0.78 |
| 7 | Medicare end stage renal disease population, 1982-87. | Health Care Financ Rev | 1990 | 0.75 |